MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2016 International Congress

    Transcranial static magnetic field stimulation (tSMS) decreases motor cortex excitability in Parkinson’s disease OFF but not ON medication

    M. Dileone, M. Carrasco-López, J. Segundo-Rodriguez, L. Mordillo-Mateos, N. López-Aristegui, F. Alonso-Frech, M. Catalan-Alonso, J. Obeso, A. Oliviero, G. Foffani (Madrid, Spain)

    Objective: To test the ability of transcranial static magnetic field stimulation (tSMS) to decrease motor cortex excitability in patients with Parkinson's disease OFF vs, ON…
  • 2016 International Congress

    Duodopa treatment experience in Oradea

    M. Sabau, L. Botnaru, A. Badea, C. Dudas (Oradea, Romania)

    Objective: We want to present our results in Duodopa treatment for advanced Parkinson's disease (PD). Background: A center for advanced PD was created in our…
  • 2016 International Congress

    Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry

    W. Poewe, T. Kimber, B. Bermans, P. Odin, A. Antonini, O. Bajenaru, K. Onuk, A. Yegin, L. Bergmann, K.R. Chaudhuri (Innsbruck, Austria)

    Objective: To evaluate the effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on motor fluctuations and dyskinesia in…
  • 2016 International Congress

    Medication use patterns vary across expert Parkinson’s disease clinics

    P. Schmidt, F. Cubillos, T. Simuni, C. Marras, T. Davis, E.C. Nelson (Miami, FL, USA)

    Objective: This analysis aims to describe and quantify the medication patterns for patients with Parkinson's disease (PD) managed in expert clinics. Background: Antiparkinson medication use…
  • 2016 International Congress

    Association between clinical features and pre- and post-synaptic dopaminergic dysfunction in multiple system atrophy: [18F]-FP-CIT PET and [18F]-FDG PET analyses

    H.S. Ryu, M. Oh, M.J. Kim, S. You, Y.J. Kim, J. Kim, K. Kim, H. Moon, J. Oh, J.S. Kim, S.J. Chung (Seoul, Korea)

    Objective: To investigate the correlation between clinical features and pre- and post-synaptic dopaminergic dysfunction in patients with multiple system atrophy (MSA). Background: Multiple system atrophy…
  • 2016 International Congress

    Influence of levodopa on functional brain connectivity in Parkinson’s disease

    S. Kobayashi, K. Asano, N. Matsuda, H. Kubo, M. Abe, Y. Ugawa (Fukushima-shi, Japan)

    Objective: To evaluate how functional connectivity estimated by resting-state functional magnetic resonance imaging (rs-fMRI) is influenced by levodopa and associated with clinical symptoms in Parkinson's…
  • 2016 International Congress

    Impact of chronic LD treatment on metabolism, blood flow and blood-brain barrier permeability in the 6-OHDA rat model

    R.P. Lerner, Z. Bimpisidis, V. Jourdain, T. Chaly, M. Hellman, K. Graf, V. Dhawan, S. Dewey, A. Cenci, D. Eidelberg (Manhasset, NY, USA)

    Objective: To determine the effects of chronic LD treatment and induction of dyskinesias on cerebral metabolism, blood flow and blood-brain barrier permeability in 6-OHDA rat…
  • 2016 International Congress

    Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease

    T. Willows, N. Dizdar, D. Nyholm, H. Widner, P. Grenholm, U. Schmiauke, A. Urbom, K. Groth, J. Larsson, J. Permert, S. Kjellander (Huddinge, Sweden)

    Objective: To demonstrate feasibility of TM for LCIG home titration, evaluate resource use, and assess patient, neurologist and nurse satisfaction. Background: LCIG, is used for…
  • 2016 International Congress

    Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study

    P. Havránková, J. Klempír, M. Fialová, A. Rezková, J. Petrtýl, V. Capek, E. Ruzicka, J. Roth, R. Jech (Praha, Czech Republic)

    Objective: To evaluate long-term efficacy, levodopa dose changes and complications in patients with advanced Parkinson's disease (PD) treated. Background: Administrated via percutaneous gastric gastrostomy to…
  • 2016 International Congress

    Safety and tolerability of inhaled levodopa (CVT-301) administered to Parkinson’s disease patients with motor fluctuations

    R. Pahwa, P. LeWitt, A. Corbin, R. Batycky, H. Murck (Kansas City, KS, USA)

    Objective: Two Phase 2 studies were conducted to evaluate the safety profile of inhaled CVT-301 administered to Parkinson's disease (PD) patients with motor fluctuations. Background:…
  • « Previous Page
  • 1
  • …
  • 58
  • 59
  • 60
  • 61
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley